Valecia Vaughn
Psychiatric/Mental Health · Opelousas, LANPI 1811339591
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 243 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 243 payments — averaging $33.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$935
- Indivior Inc.$897
- Teva Pharmaceuticals USA, Inc.$746
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$688
- plus $3K from 12 others
What the payments were for
- Food & beverage$8,06699%
- Education$1221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 37 | $1,247 |
| Otsuka America Pharmaceutical, Inc. | 26 | $1,032 |
| Alkermes, Inc. | 28 | $935 |
| Indivior Inc. | 57 | $897 |
| Teva Pharmaceuticals USA, Inc. | 26 | $746 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $688 |
| Neurocrine Biosciences, Inc. | 15 | $561 |
| AbbVie | 4 | $460 |
| Sanofi | 3 | $364 |
| Gilead | 3 | $243 |
| AstraZeneca(2 entities) | 3 | $238 |
| Neurelis, Inc. | 2 | $203 |
| Lundbeck LLC | 9 | $166 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| Novo Nordisk | 1 | $123 |
| Agile Therapeutics, Inc. | 2 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$892
- LYBALVI$871
- ABILIFY MAINTENA$479
- INVEGA SUSTENNA$374
- ABILIFY ASIMTUFII$357
- CAPLYTA$353
- SPRAVATO$348
- VRAYLAR$342
- INVEGA TRINZA$251
- FABRAZYME$246
- INGREZZA$245
- DUPIXENT$237
- REXULTI$227
- ARISTADA INITIO$223
- INVEGA$128
- Fanapt$125
- Saxenda$123
- Wegovy$123
- Austedo XR$122
- AUSTEDO$121
How this compares
$8,188 in reported general payments places this provider in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 106 | $317,210 |
| IngrezzaValbenazine Tosylate | 20 | $179,704 |
| Abilify MaintenaAripiprazole | 51 | $149,314 |
| AustedoDeutetrabenazine | 13 | $76,241 |
| Austedo XrDeutetrabenazine | 12 | $72,040 |
| CaplytaLumateperone Tosylate | 12 | $21,412 |
| Haloperidol Decanoate | 97 | $5,584 |
| Olanzapine OdtOlanzapine | 21 | $1,685 |
| Fluphenazine Hcl | 18 | $1,493 |
| Aripiprazole | 65 | $1,151 |
| Haloperidol | 31 | $1,079 |
| Quetiapine Fumarate | 51 | $616 |
| Olanzapine | 18 | $471 |
| Benztropine Mesylate | 34 | $460 |
| Risperidone | 25 | $363 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,247 | $317,210106 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $561 | $179,70420 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,032 | $149,31451 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $746 | $148,28125 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $688 | $21,41212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Opelousas
- Amy LacoutureBaton Rouge$663K
- Amanda EymardHouma$617K
- Amber LittlefieldBroussard$225K
- Timothy PellegrinHouma$210K
- Melissa GuilbeauLafayette$122K
- Kimberly ForcinelShreveport$92K
- Sattaria DilksLake Charles$57K
- Joe TaylorHammond$38K
- Lecy AlbaradoScott$34K
- Michelle DyerLake Charles$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.